BioCentury on BioBusiness,
Emerging Company Profile
Encycle's macrocycles incorporate key features that ensure drug-likeness
Related tables, figures and sidebars
Encycle: Oral macrocycles
Monday, August 4, 2014
Macrocycle therapies can block protein-protein interactions that are
undruggable with small molecules; however, oral availability and cell
penetration remain key challenges. Encycle
Therapeutics Inc.'s chemistry platform generates drug-like
macrocycles against validated targets to treat diseases for which oral
therapies are needed.
inhibitors of protein-protein interactions include
biologics and other molecules large enough to target the wide, shallow surfaces
involved in those interactions, but can only bind extracellular targets.
Macrocycles can have sufficient size to block protein-protein interactions yet
remain small enough to penetrate cells and block intracellular interactions
that biologics and small molecules cannot.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]